Rocket Pharmaceuticals (RCKT) Assets Average (2015 - 2026)

Rocket Pharmaceuticals (RCKT) has 11 years of Assets Average data on file, last reported at $307.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 38.34% year-over-year to $307.9 million; the trailing twelve-month figure through Mar 2026 stood at $307.9 million (down 38.34% YoY), and the FY2025 full-year result was $429.1 million, down 21.56% from the prior year.
• Assets Average fell to $307.9 million in Q1 2026, from $349.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $532.9 million in Q1 2024 to a low of $1.0 million in Q2 2022.
• A 5-year average of $278.1 million and a median of $307.9 million in 2026 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 30820.33% in 2024 and sank 38.34% in 2026, its largest moves.
• Tracing RCKT's Assets Average over 5 years: stood at $276.8 million in 2022, then gained by 2.61% to $284.0 million in 2023, then jumped by 62.21% to $460.7 million in 2024, then retreated by 24.19% to $349.2 million in 2025, then retreated by 11.83% to $307.9 million in 2026.
• Business Quant data shows RCKT's Assets Average at $307.9 million in Q1 2026, $349.2 million in Q4 2025, and $394.5 million in Q3 2025.